1차 출처 기록
회사는 Anaphylm 설하 필름에 대한 인간 요인 검증 연구 및 약동학 연구에서 긍정적인 결과를 발표했습니다. 이 데이터는 제1형 알레르기 반응(아나필락시스 포함) 치료를 위한 NDA의 FDA 재제출 계획을 뒷받침합니다.
aqst-20260810 0001398733 false 0001398733 2026-08-10 2026-08-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2026 Aquestive Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-38599 82-3827296 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 30 Technology Drive Warren , NJ 07059 ( 908 ) 941-1900 (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices) Not Applicable (Former name or former address, if changed since last report) ______________________